Gastroenterology | Phase II/ Phase III Developments

Allergan plc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

IRELAND Ireland

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

AstraZeneca Regains Global Rights to Brazikumab From Allergan

Lead Product(s): Brazikumab

Therapeutic Area: Gastroenterology

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: AstraZeneca PLC

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Termination May 11, 2020

Details:

AstraZeneca and Allergan have terminated their previous license agreement and all rights to brazikumab have therefore now returned to AstraZeneca.

Allergan plc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

IRELAND Ireland

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep

Lead Product(s): Brazikumab

Therapeutic Area: Gastroenterology

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: AstraZeneca PLC

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Divestment January 27, 2020

Details:

AstraZeneca will acquire brazikumab, in Phase 2b/3 development for Crohn's Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights.

Ritter Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ISPE Manufacturing

Participation Not Confirmed

Update your events

Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement

Lead Product(s): Galacto-oligosaccharide

Therapeutic Area: Gastroenterology

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Qualigen

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Merger January 21, 2020

Details:

The merged company will focus on the development of Qualigen’s nanotechnology therapies for the treatment of cancer and infectious diseases, while also continuing to operate its profitable diagnostic business.

Find

Find Gastroenterology Drugs in Phase II/III Clinical Development

Phase II/ Phase III

A collaboration with SCORR Marketing

Product Type

Companies

Allergan plc

AstraZeneca Regains Global Rights to Brazikumab From Allergan

Allergan plc

AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement